S Science
5721
Aun Consulting
2459
Tripla
5136
Flight Solutions
3753
Migalo Holdings
5535
JP Stock MarketDetailed Quotes
4575 CanBas
- 996
- -16-1.58%
20min DelayNot Open Mar 18 15:30 JST
19.04BMarket Cap-14.67P/E (Static)
1007High980Low258.50KVolume996Open1012Pre Close256.65MTurnover151252wk High1.46%Turnover Ratio19.11MShares42952wk Low-71.3EPS TTM17.59BFloat Cap4530Historical HighLossP/E (Static)17.66MShs Float162Historical Low-67.9EPS LYR2.67%Amplitude--Dividend TTM6.30P/B100Lot Size--Div YieldTTM
About CanBas Company
CanBas Co Ltd focuses on the discovery and development of novel oncology drugs targeting the cell cycle. Its product, CBP501 the anticancer drug candidate is a modified synthetic peptide which enhances the efficacy of cisplatin without adding toxicity.
Company Profile
Symbol4575
Company NameCanBas
Founded2000-01-18
MarketTSE Growth
Fiscal Year Ends06-30
Address2-2-1 Otemachi Numazu
Zip Code410-0801
Phone055-954-3666
Websitewww.canbas.co.jp
Company Executives
- Name
- Position
- Salary
- Makoto Katozumi
- Chief Financial Officer and Head of Corporate Planning
- --
- Kazuyoshi Sakamoto
- Director and Manager of Administration
- --
- Takumi Kawabe
- Representative Director and President
- --
- Akira Shirakawa
- Independent Director
- --
- Yasuyuki Komiyama
- Independent Director
- --
- Toshio Furuta
- Independent Director
- --